Navigation Links
Xanodyne Announces Planned President & CEO Succession
Date:5/27/2010

NEWPORT, Ky., May 27 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce that Natasha Giordano has been named to the position of President and Chief Executive Officer and will be elected to the Company's Board of Directors, succeeding Michael J. Valentino.

The management transition was planned by the Board and follows a year of significant new product and commercial successes under Mr. Valentino's leadership.  In 2009, Xanodyne received FDA approval for Zipsor®, a new treatment option indicated for relief of mild to moderate acute pain in adults.  The Company also received FDA approval for Lysteda™ indicated for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.  Recently, Xanodyne announced that is has tightly focused the strategic direction for the company on the pain management market, and the related sale of Lysteda™ to Ferring Pharmaceuticals.  Xanodyne has a strategic partnership with Ferring for the co-promotion of Zipsor®.

Ms. Giordano most recently served as the company's Chief Operating Officer during this period of unprecedented success.  Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and prior to Xanodyne served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry.  Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.

Ms. Giordano said, "I look forward to working with the Board and management team in continuing to drive toward our vision of being a leader in the pain management category.  We have a proven track record of bringing innovative products to the market, and developing strategic partnerships where desired,  as well as the people, resources and strategy to focus Xanodyne on high growth opportunities within the pain franchise."

Mr. Valentino said, "I am very pleased to be leaving Xanodyne with high caliber talent on the management team, and throughout the organization.  Natasha's knowledge of the industry and her continued strong leadership will sustain the momentum as Xanodyne focuses its growth in pain management. The successful launch of Zipsor®, the portfolio of legacy brands, and strategic divestiture of non-core assets, including Lysteda™, position Xanodyne well for the future."

Rolf Classon, Chairman of the Board said, "We are very pleased with this planned leadership succession.  Mike expanded his Board responsibility to include the CEO role last year with the intent of seeing our drugs through approval and commercialization, and building a team to refine the strategic direction of the business.  The successful partnership between Mike and Natasha allows us a smooth senior management transition as we move forward and execute against our strategic priorities. On behalf of myself and the Board, I'd like to thank Mike for his contributions to the Board and for his stewardship of the Company during this crucial year. "

About Xanodyne Pharmaceuticals, Inc.

Xanodyne, which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused exclusively on pain management. Xanodyne markets a portfolio of products consisting of prescription pain management pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing its pipeline of product candidates targeted at significant potential segments of the pain management market including chronic and severe pain. For more information visit www.Xanodyne.com.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
2. Xanodyne Announces Renewed Focus on Pain Management Market
3. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
4. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
5. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
6. China Yongxin Pharmaceuticals Announces 1-for-12 Reverse Stock Split
7. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
8. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
9. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
10. FDA Announces Collaboration With Drugs.com
11. VisEn Announces New ProSense® 750 FAST and Neutrophil Elastase™ 680 FAST Fluorescence Molecular Imaging Agents at European Molecular Imaging Meeting 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities ... ... ... ... ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 ... and endovascular medical technology, today announced Food and ... a cardiac resynchronization defibrillator that provides heart failure ... (MRI) scans. Iperia devices also have remote monitoring ... (CLS) that adapts the heart rate in response ...
(Date:5/3/2016)... DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to honor ... story and encourage those at risk to get tested and begin the road to a ... ... ... Pharmacy, Inc.) ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... DNA or RNA from a random library of sequences depending on their attraction ... or diagnostic agents. SELEX selection is commonly performed using filters, panning, or affinity ...
(Date:5/3/2016)... ... May 03, 2016 , ... BioPlus Specialty ... be represented at the 2016 Asembia Specialty Pharmacy Summit held May 2-6, 2016 ... largest U.S. health care conference for the specialty pharmacy industry, with thousands of ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its ... situations or practice tricky or rare procedures in an environment that looks and feels ... is also available to inventors and “hackers” to develop and test new devices or ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... advisory organization, announces Benefits Alliance Insurance Services as the latest addition to its ... California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The ...
(Date:5/3/2016)... ... May 03, 2016 , ... Huntington Beach orthopedic doctor , Dr. Rick ... can be used to diagnose and treat joint problems. During this procedure, Dr. Pospisil ... a special lighting system and lens that illuminate and magnify the various structures in ...
Breaking Medicine News(10 mins):